Risk and Return Analysis of Indian Pharmaceutical Industry – A Study

Abstract

The risk and returns analysis of the pharmaceutical industry is important in the process of making investment decisions. It allows investors to determine, whether the pharmaceutical stocks are viable in terms of returns when compared to the risks of the stocks, and hence informs investor decision making. The pharmaceutical industry is also viewed as a defensive industry because the demand of medicine is usually relatively stable even in times of economic decline, offering clues on the stability and its capacity to withstand the recession. Additionally, the analysis of the correlation between pharmaceutical stocks and the general market would help investors to have a successful portfolio diversification. By knowing the trend of the pharma stocks against the rest of the sectors, investors will be able to streamline their investments and minimize the risk factor, as a whole. Performance evaluation is another area of application of the risk and return analysis that will be used to ascertain whether the pharmaceutical sector is outperforming or underperforming the entire stock market within a specified timeframe. Lastly, the appraisal of the financial performance of the pharmaceutical industry is insightful information to both policy makers and researchers. It emphasizes the role played by the sector in economic development, job creation, and national building, making it possible to develop evidence-based policies and planning of the healthcare and industrial sectors.
This study examines the risk-return behavior of the pharmaceutical sector in India over a ten-year period from 2015–16 to 2024–25. The pharmaceutical industry plays a critical role in the Indian economy and has gained increased attention from investors, particularly in the post-pandemic period. The primary objective of this research is to analyze the performance and risk characteristics of the sector in relation to the broader market. The study employs both descriptive and analytical research methodologies. Key financial metrics such as the Sharpe Ratio, Beta (β), and correlation coefficient are used to evaluate risk-adjusted returns, systematic risk, and the relationship between the pharmaceutical sector and the market index. Additionally, rolling returns are calculated to assess consistency and variability in sector performance over time. Secondary data has been collected from reliable financial databases and stock market reports for the specified period. The findings of the study provide insights into whether the pharmaceutical sector offers superior risk-adjusted returns and how sensitive it is to overall market movements. The results are expected to assist investors, portfolio managers, and policymakers in making informed decisions regarding investment in the pharmaceutical sector.